Selected research
Industry Research
Antipyretic Medicine for Infants and Young Children Industry Research Report 2026
Market perspective
The global Antipyretic Medicine for Infants and Young Children market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antipyretic Medicine for Infants and Young Children market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antipyretic Medicine for Infants and Young Children market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antipyretic Medicine for Infants and Young Children market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antipyretic Medicine for Infants and Young Children include Anqiu Lu'an, Atabay, Farmson, Granules Biocause, Granules India, IOLCP, Mallinckrodt, Novacyl and SKPL, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antipyretic Medicine for Infants and Young Children market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antipyretic Medicine for Infants and Young Children.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antipyretic Medicine for Infants and Young Children Market by Company
Anqiu Lu'an
Atabay
Farmson
Granules Biocause
Granules India
IOLCP
Mallinckrodt
Novacyl
SKPL
Strides Shasun
Temad
Anhui BBCA Likang
Anhui Fubore
Hebei Jiheng
Xinhua Pharmaceutical
Zhejiang Kangle
Antipyretic Medicine for Infants and Young Children Segment by Type
Acetaminophen
Ibuprofen
Other
Antipyretic Medicine for Infants and Young Children Segment by Application
Online Sales
Offline Sales
Antipyretic Medicine for Infants and Young Children Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antipyretic Medicine for Infants and Young Children market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antipyretic Medicine for Infants and Young Children and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antipyretic Medicine for Infants and Young Children.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antipyretic Medicine for Infants and Young Children companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Acetaminophen
- Ibuprofen
- Other
Applications
- Online Sales
- Offline Sales
Companies covered
- Anqiu Lu'an
- Atabay
- Farmson
- Granules Biocause
- Granules India
- IOLCP
- Mallinckrodt
- Novacyl
- SKPL
- Strides Shasun
- Temad
- Anhui BBCA Likang
- Anhui Fubore
- Hebei Jiheng
- Xinhua Pharmaceutical
- Zhejiang Kangle
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antipyretic Medicine for Infants and Young Children by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Acetaminophen
- 2.2.3 Ibuprofen
- 2.2.4 Other
- 2.3 Antipyretic Medicine for Infants and Young Children by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Online Sales
- 2.3.3 Offline Sales
- 2.4 Assumptions and Limitations
3 Antipyretic Medicine for Infants and Young Children Breakdown Data by Type
- 3.1 Global Antipyretic Medicine for Infants and Young Children Historic Market Size by Type (2021-2026)
- 3.2 Global Antipyretic Medicine for Infants and Young Children Forecasted Market Size by Type (2027-2032)
4 Antipyretic Medicine for Infants and Young Children Breakdown Data by Application
- 4.1 Global Antipyretic Medicine for Infants and Young Children Historic Market Size by Application (2021-2026)
- 4.2 Global Antipyretic Medicine for Infants and Young Children Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antipyretic Medicine for Infants and Young Children Market Perspective (2021-2032)
- 5.2 Global Antipyretic Medicine for Infants and Young Children Growth Trends by Region
- 5.2.1 Global Antipyretic Medicine for Infants and Young Children Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antipyretic Medicine for Infants and Young Children Historic Market Size by Region (2021-2026)
- 5.2.3 Antipyretic Medicine for Infants and Young Children Forecasted Market Size by Region (2027-2032)
- 5.3 Antipyretic Medicine for Infants and Young Children Market Dynamics
- 5.3.1 Antipyretic Medicine for Infants and Young Children Industry Trends
- 5.3.2 Antipyretic Medicine for Infants and Young Children Market Drivers
- 5.3.3 Antipyretic Medicine for Infants and Young Children Market Challenges
- 5.3.4 Antipyretic Medicine for Infants and Young Children Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antipyretic Medicine for Infants and Young Children Players by Revenue
- 6.1.1 Global Top Antipyretic Medicine for Infants and Young Children Players by Revenue (2021-2026)
- 6.1.2 Global Antipyretic Medicine for Infants and Young Children Revenue Market Share by Players (2021-2026)
- 6.2 Global Antipyretic Medicine for Infants and Young Children Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antipyretic Medicine for Infants and Young Children Head Office and Area Served
- 6.4 Global Antipyretic Medicine for Infants and Young Children Players, Product Type & Application
- 6.5 Global Antipyretic Medicine for Infants and Young Children Manufacturers Established Date
- 6.6 Global Antipyretic Medicine for Infants and Young Children Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antipyretic Medicine for Infants and Young Children Market Size (2021-2032)
- 7.2 North America Antipyretic Medicine for Infants and Young Children Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antipyretic Medicine for Infants and Young Children Market Size by Country (2021-2026)
- 7.4 North America Antipyretic Medicine for Infants and Young Children Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antipyretic Medicine for Infants and Young Children Market Size (2021-2032)
- 8.2 Europe Antipyretic Medicine for Infants and Young Children Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antipyretic Medicine for Infants and Young Children Market Size by Country (2021-2026)
- 8.4 Europe Antipyretic Medicine for Infants and Young Children Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antipyretic Medicine for Infants and Young Children Market Size (2021-2032)
- 9.2 Asia-Pacific Antipyretic Medicine for Infants and Young Children Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antipyretic Medicine for Infants and Young Children Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antipyretic Medicine for Infants and Young Children Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antipyretic Medicine for Infants and Young Children Market Size (2021-2032)
- 10.2 South America Antipyretic Medicine for Infants and Young Children Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antipyretic Medicine for Infants and Young Children Market Size by Country (2021-2026)
- 10.4 South America Antipyretic Medicine for Infants and Young Children Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antipyretic Medicine for Infants and Young Children Market Size (2021-2032)
- 11.2 Middle East & Africa Antipyretic Medicine for Infants and Young Children Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antipyretic Medicine for Infants and Young Children Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antipyretic Medicine for Infants and Young Children Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Anqiu Lu'an
- 12.1.1 Anqiu Lu'an Company Information
- 12.1.2 Anqiu Lu'an Business Overview
- 12.1.3 Anqiu Lu'an Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.1.4 Anqiu Lu'an Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.1.5 Anqiu Lu'an Recent Developments
- 12.2 Atabay
- 12.2.1 Atabay Company Information
- 12.2.2 Atabay Business Overview
- 12.2.3 Atabay Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.2.4 Atabay Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.2.5 Atabay Recent Developments
- 12.3 Farmson
- 12.3.1 Farmson Company Information
- 12.3.2 Farmson Business Overview
- 12.3.3 Farmson Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.3.4 Farmson Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.3.5 Farmson Recent Developments
- 12.4 Granules Biocause
- 12.4.1 Granules Biocause Company Information
- 12.4.2 Granules Biocause Business Overview
- 12.4.3 Granules Biocause Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.4.4 Granules Biocause Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.4.5 Granules Biocause Recent Developments
- 12.5 Granules India
- 12.5.1 Granules India Company Information
- 12.5.2 Granules India Business Overview
- 12.5.3 Granules India Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.5.4 Granules India Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.5.5 Granules India Recent Developments
- 12.6 IOLCP
- 12.6.1 IOLCP Company Information
- 12.6.2 IOLCP Business Overview
- 12.6.3 IOLCP Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.6.4 IOLCP Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.6.5 IOLCP Recent Developments
- 12.7 Mallinckrodt
- 12.7.1 Mallinckrodt Company Information
- 12.7.2 Mallinckrodt Business Overview
- 12.7.3 Mallinckrodt Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.7.4 Mallinckrodt Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.7.5 Mallinckrodt Recent Developments
- 12.8 Novacyl
- 12.8.1 Novacyl Company Information
- 12.8.2 Novacyl Business Overview
- 12.8.3 Novacyl Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.8.4 Novacyl Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.8.5 Novacyl Recent Developments
- 12.9 SKPL
- 12.9.1 SKPL Company Information
- 12.9.2 SKPL Business Overview
- 12.9.3 SKPL Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.9.4 SKPL Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.9.5 SKPL Recent Developments
- 12.10 Strides Shasun
- 12.10.1 Strides Shasun Company Information
- 12.10.2 Strides Shasun Business Overview
- 12.10.3 Strides Shasun Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.10.4 Strides Shasun Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.10.5 Strides Shasun Recent Developments
- 12.11 Temad
- 12.11.1 Temad Company Information
- 12.11.2 Temad Business Overview
- 12.11.3 Temad Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.11.4 Temad Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.11.5 Temad Recent Developments
- 12.12 Anhui BBCA Likang
- 12.12.1 Anhui BBCA Likang Company Information
- 12.12.2 Anhui BBCA Likang Business Overview
- 12.12.3 Anhui BBCA Likang Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.12.4 Anhui BBCA Likang Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.12.5 Anhui BBCA Likang Recent Developments
- 12.13 Anhui Fubore
- 12.13.1 Anhui Fubore Company Information
- 12.13.2 Anhui Fubore Business Overview
- 12.13.3 Anhui Fubore Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.13.4 Anhui Fubore Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.13.5 Anhui Fubore Recent Developments
- 12.14 Hebei Jiheng
- 12.14.1 Hebei Jiheng Company Information
- 12.14.2 Hebei Jiheng Business Overview
- 12.14.3 Hebei Jiheng Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.14.4 Hebei Jiheng Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.14.5 Hebei Jiheng Recent Developments
- 12.15 Xinhua Pharmaceutical
- 12.15.1 Xinhua Pharmaceutical Company Information
- 12.15.2 Xinhua Pharmaceutical Business Overview
- 12.15.3 Xinhua Pharmaceutical Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.15.4 Xinhua Pharmaceutical Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.15.5 Xinhua Pharmaceutical Recent Developments
- 12.16 Zhejiang Kangle
- 12.16.1 Zhejiang Kangle Company Information
- 12.16.2 Zhejiang Kangle Business Overview
- 12.16.3 Zhejiang Kangle Revenue in Antipyretic Medicine for Infants and Young Children Business (2021-2026)
- 12.16.4 Zhejiang Kangle Antipyretic Medicine for Infants and Young Children Product Portfolio
- 12.16.5 Zhejiang Kangle Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst